

Wang Hai Ping, BaiYunQu,
JiangXiaBeiZhongLu, 8 Hao, C Dong,
609 Shi, Guang Zhou, Guang Dong,
510080, China

ShenzhenShi Xiangfan Xinxizixun
Youxiangongsi, MinZhi JieDao
XinNiu She Qu, GangShen Guoji
ZhongXin D11-14, Shen Zhen, Guang
Dong, 518000, China

RuianShichensumaoyiyouxiangongsi,
Ding Tian Jie Dao, Liang Qian Chun,
(Long Chun He Zhou Ying Hang),
WenZhou Rui An, Zhe Jiang, 325200,
China

Qingyuannuozedianzishangwu
youxianzerengongsi, YingCheng Jie
Dao, BiGuiYuan, Yunjing, 3 Hao Luo,
1702 Fang, QinYuan YingDe,
GuangDong, 513000, China

Wuhu Tianhao e-commerce Co., Ltd,
LinAn Wu Liu Yuan 1 Qi, 12 Dong,
202 Shi, Wu Hu, An Hui, 241100,
China

shen zhen shi hong kang da ke ji you
xian gong si, LongGang Qu, JuYin KeJi
GongYeYuan, NanWan JieDao, H
dong 101, Shen Zhen, Guang Dong,
518000, China

guangzhou yingpeng dianzi shangwu
youxiangongsi, TianHe Qu, Huang
Cun Bei Lu, 26 Hao, D Qu, 2 Lou,
60397 Shi, Guang Zhou, Guang Dong,
510000, China

shen zhen shi xing han xing dian zi
shang wu you xian gong si, 25 Gao
Xin Nan Si Dao, NanShan, Shen
Zhen, Guang Dong, 518000, China

(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW, Suite
401, Washington, DC 20436; and

(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.

Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission's Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.

Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this

notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.

By order of the Commission.

Issued: June 13, 2025.

Susan Orndoff,

Acting Secretary to the Commission.

[FR Doc. 2025-11187 Filed 6-17-25; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1553]

Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services

AGENCY: Drug Enforcement
Administration, Justice.

ACTION: Notice of application.

SUMMARY: AndersonBrecon, Inc. DBA
PCI Pharma Services has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to **SUPPLEMENTARY INFORMATION**
listed below for further drug
information.

DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on, or objections to
the issuance of the proposed registration
on or before July 18, 2025. Such persons
may also file a written request for a
hearing on the application on or before
July 18, 2025.

ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
<https://www.regulations.gov> and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on <https://www.regulations.gov>. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no

need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrisette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrisette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrisette Drive, Springfield,
Virginia 22152.

SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 8, 2025,
AndersonBrecon, Inc. DBA PCI Pharma
Services, 4545 Assembly Drive,
Rockford, Illinois 61109-3081, applied
to be registered as an importer of the
following basic class(es) of controlled
substance(s):

Controlled substance	Drug code	Schedule
Tetrahydrocannabinols	7370	I
3,4-Methylenedioxymetham- phetamine.	7405	I
Dimethyltryptamine	7435	I

The company plans to import the
listed controlled substances for clinical
trials. No other activities for these drug
codes are authorized for this
registration.

Approval of permit applications will
occur only when the registrant's
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or non-
approved finished dosage forms for
commercial sale.

Matthew Strait,

Deputy Assistant Administrator.

[FR Doc. 2025-11245 Filed 6-17-25; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1559]

Importer of Controlled Substances Application: Veranova, L.P.

AGENCY: Drug Enforcement
Administration, Justice.

ACTION: Notice of application.

SUMMARY: Veranova, L.P. has applied to
be registered as an importer of basic
class(es) of controlled substance(s).
Refer to **SUPPLEMENTARY INFORMATION**
listed below for further drug
information.